



University of Southern Denmark

## One year of Football Fitness improves L1–L4 BMD, postural balance, and muscle strength in women treated for breast cancer

Uth, Jacob; Fristrup, Bjørn; Sørensen, Victor; Helge, Eva Wulff; Christensen, Maja Kjærgaard; Kjærgaard, Julie Boye; Møller, Trine Kjeldgaard; Helge, Jørn Wulff; Jørgensen, Niklas Rye; Rørth, Mikael; Vadstrup, Eva Soelberg; Krstrup, Peter

*Published in:*

Scandinavian Journal of Medicine and Science in Sports

*DOI:*

10.1111/sms.13963

*Publication date:*

2021

*Document version:*

Accepted manuscript

*Citation for pulished version (APA):*

Uth, J., Fristrup, B., Sørensen, V., Helge, E. W., Christensen, M. K., Kjærgaard, J. B., Møller, T. K., Helge, J. W., Jørgensen, N. R., Rørth, M., Vadstrup, E. S., & Krstrup, P. (2021). One year of Football Fitness improves L1–L4 BMD, postural balance, and muscle strength in women treated for breast cancer. *Scandinavian Journal of Medicine and Science in Sports*, 31(7), 1545-1557. <https://doi.org/10.1111/sms.13963>

Go to publication entry in University of Southern Denmark's Research Portal

### Terms of use

This work is brought to you by the University of Southern Denmark.

Unless otherwise specified it has been shared according to the terms for self-archiving.

If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to [puresupport@bib.sdu.dk](mailto:puresupport@bib.sdu.dk)

1

2 MR JACOB UTH (Orcid ID : 0000-0003-0619-7134)

3 DR EVA WULFF HELGE (Orcid ID : 0000-0002-4351-0137)

4 PROFESSOR PETER KRUSTRUP (Orcid ID : 0000-0002-1461-9838)

5

6

7 Article type : Original Article

8

9

10 **One year of Football Fitness improves L1-L4 BMD, postural balance and muscle strength in**  
11 **women treated for breast cancer**

12 Authors:

13 Jacob Uth<sup>1,2#</sup>, Bjørn Frstrup<sup>2</sup>, Victor Sørensen<sup>1,5</sup>, Eva Wulff Helge<sup>3</sup>, Maja Kjærgaard Christensen<sup>3</sup>,  
14 Julie Boye Kjærgaard<sup>3</sup>, Trine Kjeldgaard Møller<sup>2</sup>, Jørn Wulff Helge<sup>4</sup>, Niklas Rye Jørgensen<sup>5,6</sup>,  
15 Mikael Rørth<sup>7,8</sup>, Eva Soelberg Vadstrup<sup>8</sup>, Peter Krustrup<sup>2,9</sup>

16

17 Corresponding author:

18 Jacob Uth, email: [jaut@kp.dk](mailto:jaut@kp.dk)

19 Authors' affiliations:

20 1: University Hospitals Centre for Health Research, Copenhagen University Hospital,  
21 Rigshospitalet, Copenhagen, Denmark;

22 2: Department of Sports Science and Clinical Biomechanics, Section of Sport and Health Sciences,  
23 University of Southern Denmark, Odense, Denmark;

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/SMS.13963](https://doi.org/10.1111/SMS.13963)

This article is protected by copyright. All rights reserved

- 1 3: Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen,  
2 Denmark;
- 3 4: Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
- 4 5: Department of Clinical Biochemistry, Copenhagen University Hospital, Rigshospitalet,  
5 Copenhagen, Denmark;
- 6 6: Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;
- 7 7: Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark;
- 8 8: Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen,  
9 Denmark;
- 10 9: Danish Institute for Advanced Study (DIAS), University of Southern Denmark, Odense,  
11 Denmark.

12  
13  
14 # Jacob Uth's current affiliation is at Copenhagen University College, Department of  
15 Physiotherapy, Copenhagen, Denmark

## 16 Abstract

17 Purpose. To examine efficacy of 12 months Football Fitness offered twice per week on bone  
18 mineral density (BMD), bone turnover markers (BTM), postural balance, muscle strength and body  
19 composition in women treated for early-stage breast cancer (BC).

20 Methods. Women treated for early-stage BC were randomised to Football Fitness (FFG, n=46) or  
21 control (CON, n=22) in a 2:1 ratio for 12 months, with assessments performed at baseline, 6 months  
22 and 12 months. Outcomes were total body-, lumbar spine- and proximal femur BMD, total body  
23 lean and fat mass, leg muscle strength, postural balance, and plasma amino-terminal propeptide of  
24 type 1 procollagen (P1NP), osteocalcin and C-terminal telopeptide of type 1 collagen (CTX).  
25 Intention-to-treat (ITT) analyses and per-protocol analyses ( $\geq 50\%$  attendance in FFG) were  
26 performed using linear mixed models.

27 Results. Participants in FFG completing the 12-month intervention (n=33) attended 0.8 (SD=0.4)  
28 sessions per week. Intention to treat analysis of mean changes over 12 months showed significant

1 differences in L1-L4 BMD (0.029 g/cm<sup>2</sup>, 95%CI: 0.001 to 0.057), leg press strength (7.2 kg,  
2 95%CI: 0.1 to 14.3) and postural balance (-4.3 n need of support, 95%CI: -8.0 to -0.7) favouring  
3 FFG compared to CON. In the per-protocol analyses, L1-L4 and trochanter major BMD were  
4 improved (p=0.012 and 0.030, respectively) in FFG compared to CON. No differences were  
5 observed between groups in BTMs in the ITT or per protocol analyses.

6 Conclusion. One year of Football Fitness training may improve L1-L4 BMD, leg muscle strength  
7 and postural balance in women treated for early-stage breast cancer.

8

### 9 Acknowledgements

10 We would like to thank The Preben & Anna Simonsen Foundation and the Lundbeck Foundation  
11 for provided funding for this trial. Also, we would like to thank all participants for their  
12 contributions to the trial, and Christian Lillelund for performing physiological assessment tests,  
13 Frederik Sørensen for providing expert statistical advice, and Birgitte Rasmussen for providing data  
14 from participants' medical records. Finally, we would like to thank the Department of Nutrition,  
15 Exercise and Sports for providing training facilities and the management and staff in the  
16 Department of Oncology at the University Hospital of Copenhagen, Rigshospitalet, for their  
17 commitment to the trial and help with recruiting the participants.

18

### 19 Trial registration number

20 The trial was registered at ClinicalTrials.gov with identifier NCT03284567.

21 Keywords: bone mineral density, breast cancer rehabilitation, soccer, bone turnover, flamingo  
22 balance test, bone turnover markers

23

### 24 1 Introduction

25 Breast cancer is the most common cancer in Danish women, with around 4,700 new cases annually.  
26 In recent decades, early diagnosis and improved treatment have led to higher survival rates, with a  
27 current 5-year survival rate of 87%, and currently 66,000 women in Denmark are living with a  
28 diagnosis of breast cancer <sup>1</sup>. While improvements in survival rates are inherently positive, adjuvant

1 chemo- and endocrine therapy are associated with detrimental effects on body composition and  
2 skeletal health <sup>2,3</sup>. Specifically, premenopausal women may lose up to 8% of lumbar spine bone  
3 mass in the first year after chemotherapy-induced amenorrhea <sup>4</sup>. In postmenopausal women with  
4 hormone-receptor-positive breast cancer, aromatase inhibitors (AIs) are standard treatment for 5  
5 years after surgery and adjuvant therapy, i.e. chemo- and radiation therapy <sup>5</sup>. While AIs improve  
6 disease-free survival, postmenopausal women on this treatment have an accelerated annual loss of  
7 bone mineral density (BMD) of ~1.5% together with increased fracture risk in addition to the  
8 normal age-related ~0.5-1% annually decline of BMD<sup>6</sup>. This is associated with increased osteoclast  
9 differentiation and activity, leading to increased bone resorption and a negative net balance in bone  
10 mass associated with remodelling <sup>7,8</sup>. As in healthy individuals, weight-bearing activities involving  
11 high-impact exercises, such as running and jumping, combined with resistance exercise are  
12 recommended training for breast cancer patients receiving AIs. The overall aim for the training is to  
13 prevent the age-related reduction in BMD leading to increased risk of osteoporosis and to improve  
14 muscle strength and postural balance to avoid risk of falling and fractures <sup>9,10</sup>. However, the role of  
15 exercise in managing late effects of cancer treatment has been less studied. A meta-analysis of  
16 seven randomised controlled trials (RCTs) of exercise interventions lasting at least 12 months in  
17 pre- and postmenopausal women treated for early-stage breast cancer showed that exercise does not  
18 maintain BMD at any site in postmenopausal women, while it may maintain femoral neck but not  
19 spine BMD in premenopausal women diagnosed with early-stage breast cancer <sup>11</sup>. However, the  
20 small number of trials and the heterogeneity of interventions and included populations warrant  
21 further studies before the role of exercise in bone health management in breast cancer patients can  
22 be defined.

23 In general, an osteogenic exercise stimulus is associated with dynamic mechanical loading that  
24 induces bone strain, preferentially with a high strain magnitude and -rate, which is covered by high-  
25 impact exercises with large ground-reaction forces and heavy resistance exercises with large joint-  
26 reaction forces <sup>12</sup>. Over the past 15 years, a comprehensive body of evidence has shown that small-  
27 sided recreational football combines endurance and high-intensity aerobic exercise, high-impact and  
28 resistance exercise, which altogether result in broad-spectrum health-promoting impact, including  
29 osteogenic effects <sup>13</sup>. Thus, the frequent high intensity bouts with accelerations and decelerations  
30 over short distances and in varied directions <sup>14</sup> induce osteogenic bone strain along varied strain  
31 axes on the weight-bearing skeleton <sup>12</sup>.

1 To achieve more knowledge on osteogenic mechanisms in humans and specifically to investigate  
2 acute and short-term effects on bone remodelling and modelling, the assessment of bone turnover  
3 markers (BTMs) is recommended. Thus, it is recommended to evaluate bone formation by the  
4 amino-terminal propeptide of type 1 procollagen (P1NP) and bone resorption by the C-terminal  
5 telopeptide of type 1 collagen (CTX), which are related to changes in habitual loading pattern of the  
6 skeleton <sup>15</sup>.

7 Football training performed 2–3 times per week for 3–4 months has been shown to improve femoral  
8 shaft and trochanter BMD in healthy, sedentary, middle-aged women <sup>16</sup> and femoral neck and  
9 femoral shaft BMD in middle-aged men and women with prediabetes <sup>17</sup>, and to improve tibial  
10 BMD, jump power and muscle strength in healthy, untrained, premenopausal women <sup>18</sup>. In the latter  
11 study, further positive effects on bone mineralisation and muscle strength was reported after 16  
12 months of football <sup>19(p2010)</sup>.

13 In men with prostate cancer, we previously tested the feasibility and efficacy of football as a novel  
14 approach to promote an active lifestyle that included high-intensity exercise, camaraderie and,  
15 potentially, long-term adherence <sup>20</sup>. We found that football was a feasible and intense exercise  
16 modality that improved muscle mass, muscle strength, physical performance, and femur shaft and  
17 total hip BMD in men undergoing androgen deprivation therapy for prostate cancer <sup>14,21</sup>, and that the  
18 effects on BMD were maintained 5 years after the initial baseline in those participants who  
19 continued to play football after the end of the supervised intervention period <sup>22</sup>. A subsequent multi-  
20 centre study (n=214) confirmed the efficacy of football as an osteogenic mode of exercise in men  
21 with prostate cancer <sup>23</sup>.

22 Taking this into account, in this secondary study of the Football Fitness After Breast Cancer trial we  
23 aimed to evaluate the effects of one year Football Fitness offered twice per week, compared to usual  
24 care, on total body, spine and hip BMD, BTMs, lean body mass, postural balance and muscle  
25 strength in women treated for stage I-III breast cancer. We hypothesised that Football Fitness would  
26 be superior to usual care with regard to effects on lumbar spine and hip BMD, muscle strength and  
27 postural balance.

## 1 2 Methods

### 2 2.1 Trial design, setting, recruitment and participants

3 Football Fitness After Breast Cancer was a randomised trial comparing Football Fitness with  
4 standard care. Women managed with either lumpectomy or mastectomy for stage I-III breast cancer  
5 were recruited from the outpatient clinic of the Department of Oncology at Copenhagen University  
6 Hospital, Rigshospitalet. When attending control visits after completion of adjuvant chemotherapy  
7 and/or radiation therapy, the women were invited by a nurse to contact the project staff for  
8 eligibility screening for the present trial. The trial was also advertised in Facebook groups for breast  
9 cancer survivors, via public news outlets and on the Danish Cancer Society's webpage. The full list  
10 of criteria for inclusion was completion of adjuvant chemotherapy and/or radiation therapy within 5  
11 years prior to randomisation, ability to read and understand Danish, age between 18 and 76 years,  
12 and WHO performance status 0-1. Exclusion criteria included planned treatment with chemotherapy  
13 or radiation therapy in the intervention period, stage IV breast cancer, osteoporosis, ongoing  
14 treatment with anticoagulants, serious cardiac morbidity including ischaemic heart disease, heart  
15 failure, poorly controlled hypertension, cardiac arrhythmia, tendency to syncope and cardiac  
16 pacemaker. Participants with a T-score of  $< -2.5$  in total hip or L1-L4 at baseline were excluded  
17 from the trial and encouraged to consult with their treating doctor for further screening for  
18 osteoporosis. Recruitment of participants began in March 2017 and ended in October 2018.

### 19 2.2 Randomisation, blinding, and sample size

20 After screening and baseline testing, the participants were randomised in a 2:1 ratio to either the  
21 Football Fitness group (FFG) or the control group (CON). The unequal allocation ratio was chosen  
22 to increase the volume of data from the intervention group, as this was the first study of its kind in  
23 this patient group. Furthermore, an unequal allocation leading to more participants to the FFG than  
24 CON ensured enough participants in FFG to form sufficiently large teams needed to carry out the  
25 intervention. A detailed description of the randomization process is reported elsewhere <sup>24</sup>.  
26 Assessment of muscle strength and postural balance was performed by study personnel blinded to  
27 group allocation, whereas DXA scans and blood sampling were performed by unblinded study  
28 personnel. Sample size was based on expected differences in changes of the primary outcome,  
29  $VO_{2max}$  which is reported elsewhere <sup>24</sup>. In brief, we calculated that 50 women should be included  
30 in FFG and 25 women in CON to obtain a power of 0.8. To account for attrition, we aimed to  
31 include 90 women treated for breast cancer.

### 1 2.3 Ethics approval

2 The trial was conducted in accordance with the Helsinki Declaration and approved by the ethics  
3 committee of the Capital Region of Copenhagen, Denmark (Registration number H-16029533). All  
4 participants gave written informed consent before any study procedures were performed.

### 5 2.4 Intervention

6 Participants in FFG were offered Football Fitness twice weekly for 12 months. Each session  
7 consisted of a 10–15-min warm-up (running, squats, sit-ups, back extensions, core-strength  
8 exercises and balance exercises), 15 min of pair- or group-based football drills (passing, dribbling,  
9 shooting) and 3–4 x 7 min of small-sided (4–5-a-side) football matches on a 15-m wide, 20-m long  
10 pitch with 2-min breaks between matches. In order to prevent injuries, participants were instructed  
11 to avoid hard tackles and to refrain from placing the foot sole on top of the ball. From mid-October  
12 to late March, sessions were performed indoors on a 15-m wide, 20-m long pitch with boundaries.  
13 Sessions were instructed and supervised by exercise physiologists or physiotherapists who also  
14 recorded attendance at each session.

### 15 2.5 Usual care

16 The participants in CON were not given any restrictions on physical activity during the intervention  
17 period and were invited to participate in Football Fitness after the 12-month intervention period.

### 18 2.6 Injuries

19 Injuries occurring in relation to Football Fitness were recorded by the instructor and, in addition, the  
20 participants in both FFG and CON filled out a questionnaire at the 12-month follow-up assessment  
21 concerning musculoskeletal injuries sustained during the intervention period.

### 22 2.7 Activity profile during Football Fitness

23 The participants' movement patterns during outdoor small-sided matches were evaluated by  
24 portable global positioning system (GPS) units (MinimaxX s5, Catapult Innovations, Canberra,  
25 Australia) with a time resolution of 10 Hz. The units were placed in a vest worn by the participants.  
26 GPS data were analysed using proprietary software (Catapult Sprints version 5.1.7 team sports).  
27 Total distance, distance of single bouts and number of accelerations in the intensity zones 0–1, 1–2,  
28 2–4 and  $> 4 \text{ m/s}^2$  were recorded. Limited access to the GPS system meant that only a subgroup of  
29 participants was included in measurements of activity profile. Heart rate during the 3–4 × 7-min  
30 small-sided matches was measured in a subsample of 15 participants in 15 sessions with a Polar  
31 Team 2 system and analysed with Polar Team 2 version 1.4.5 software.



## 1 2.8 Study outcomes

2 All assessments performed at baseline were repeated at 6- and 12-month follow-ups. The  
3 participants were instructed to avoid strenuous exercise for 48 hours before the test day and to avoid  
4 intake of alcohol for 24 hours prior to the test. The participants were also instructed to fast for at  
5 least 8 hours prior to the test and to avoid smoking and intake of caffeine and medicine, including  
6 anti-hypertensive drugs, until after the tests of the specific day were completed. DXA scans, blood  
7 pressure measurements and blood sampling were carried out in the morning between 7:30 and 10:00  
8 a.m. The participants were offered a meal, e.g. a sandwich or fruit and yoghurt, drank water and/or  
9 fruit juice and filled out questionnaires before performing tests regarding muscle strength and  
10 postural balance (see below).

### 11 2.8.1. Body composition and regional bone mineral density

12 Height was measured with a stadiometer and weight with a digital platform. Total body BMD, fat  
13 percentage and lean mass were assessed with a whole-body DXA scan (iDXA, Lunar Corporation,  
14 Madison, WI, USA), and separate scans were performed to measure BMD of the lumbar spine and  
15 proximal femur. BMD values of the upper femur region are reported as means of the right and left  
16 sides. The coefficient of variation for measurement of BMD is 1.0% according to the manufacturer.

### 17 2.8.2. Bone turnover markers

18 Blood was obtained from an antecubital vein and analysed for procollagen type 1 amino-terminal  
19 propeptide (P1NP), osteocalcin and C-terminal telopeptide of type 1 collagen (CTX) by a  
20 chemiluminescence method using a fully automated immunoassay system (iSYS,  
21 Immunodiagnostic Systems Ltd, Boldon, England).

### 22 2.8.3. Muscle strength

23 Maximal leg muscle strength was assessed using the one repetition maximum (1RM) test for leg  
24 extension and leg press using conventional resistance training machines from Technogym (Cesena,  
25 Italy). 1RM was defined as the maximum weight lifted through a full range of motion with correct  
26 technique.

### 27 2.8.4. Postural balance

28 Postural balance was assessed using the flamingo balance test <sup>25</sup>. The test has previously been used  
29 to measure postural balance in numerous populations, including men with prostate cancer <sup>14</sup> and  
30 premenopausal women <sup>18</sup>. The participants were instructed to stand with eyes open and barefooted  
31 on their dominant leg on a 5-cm high and 3-cm wide plastic bar for 1 min while keeping the

1 opposite knee flexed supported by one hand. The timing was paused each time a participant lost her  
2 balance and stepped off the bar or needed support. The number of times a participant stepped off the  
3 bar or needed support before a total of 1-min in balance was fulfilled was recorded as a measure of  
4 postural balance.

## 5 2.9 Statistical analyses

6 Descriptive statistics were reported as mean (SD) or n (%), unless stated otherwise. Differences in  
7 numeric variables at baseline were assessed by Welch two-sample t-tests, while categorical variables  
8 were assessed by Chi-squared tests. Within-group changes in outcome and differences between  
9 mean changes of groups were assessed by linear mixed-model analyses, where an unstructured  
10 covariance was assumed. Goodness of fit was assessed by residual diagnostics. Distributions of  
11 BTM were skewed and therefore log-transformed before statistical analysis and represented as  
12 median with interquartile ranges (IQR), range and outliers ( $>1.5 \times$  IQR). Within-group changes in  
13 outcome and differences between mean changes of groups were reported as mean (95% confidence  
14 intervals). For translatability, estimated differences between mean changes of the groups are  
15 accompanied by percentage change. To test the efficacy of Football Fitness, a per-protocol analysis  
16 was performed, including only participants who participated in  $\geq 50\%$  of the possible Football  
17 Fitness sessions and, from the control group, only participants who attended all test days. Change  
18 values between participants who participated in  $\geq 50\%$  were compared to those who participated  
19 less with Welch two-sample t-tests. An additional secondary analysis excluding all participants  
20 receiving bisphosphonates were performed for BMD and BTM outcomes. To further explore  
21 responsiveness, participants in the intervention group were grouped in responders and non-  
22 responders. Statistical significance was considered as  $P < 0.05$ . Linear mixed-model analyses were  
23 statistically processed using SAS software, version 7.1 (SAS Institute, Cary, NC), while the other  
24 above-mentioned statistical analyses and generation of figures were processed in R (RStudio Team,  
25 Inc., Boston, MA).

## 26 3. Results

### 27 3.1 Study sample

28 From March 2017 to October 2018, 81 women treated for breast cancer and interested in the study  
29 were screened for eligibility (see Fig. 1). The first and last participants were baseline-tested on 29  
30 March 2017 and 3 October 2018, respectively. Reasons for exclusion before baseline assessment  
31 were lack of time or long travel distance ( $n=7$ ), self-reported low BMD ( $n=1$ ) and musculoskeletal

1 injury (n=1). Of 72 women assessed at baseline, 4 were excluded due to BMD  $\leq$  -2.5 or feeling  
2 uncomfortable after completing the tests while fasting. In total, 68 women were randomised to  
3 either the Football Fitness group (n=46) or the control group (n=22) after baseline assessment. Five  
4 participants allocated to FFG did not start the Football Fitness intervention. One participant broke  
5 her leg while hiking on vacation after the baseline test and before the intervention started, and 4  
6 regretted signing up to the trial for personal reasons, e.g. family and work obligations. Demographic  
7 and clinical characteristics are presented in Table 1. Retention in FFG was 76% and 72% at 6 and  
8 12 months, respectively. The corresponding numbers for CON were 86% and 73%. 50% and 45%  
9 received calcium supplementation in FFG and CON, respectively. 54% and 45% received Vitamin  
10 D supplementation in FFG and CON, respectively. Some participants received multivitamins  
11 (n=20), magnesium (n=7), regular analgesics (n=2), blood pressure medications (n=3), and zinc  
12 (n=1).

### 13 3.2 Adherence to the Football Fitness intervention

14 Adherence to Football Fitness over 12 months was 44% (SD 21.6) of 92.5 (5.1) possible sessions  
15 for the 33 participants in FFG who completed the 12-month assessment, corresponding to 0.8 (0.4)  
16 sessions per week, of which 17 (52%) of the 33 participants attended >50% of possible sessions,  
17 corresponding to 1 session per week on average. Participation in the first 6 months was 50% (22.0)  
18 of 49.0 (0.8) possible sessions, corresponding to 0.9 (0.4) sessions per week for the 35 participants  
19 in FFG completing the 6-month follow-up. Six participants completing the 6-month follow-up had  
20 participated in  $\leq$  5 sessions. In the last 6 months, attendance was 43% (26.4) of 43.5 (4.7) possible  
21 sessions, corresponding to 0.7 (0.5) sessions per week.

### 22 3.3 Injuries

23 During 1 year of Football Fitness, 21 injuries were recorded in 15 participants (See Table 1 in the  
24 Electronic Supplementary Material (ESM)). Most injuries were related to football drills (n=6) or  
25 matches (n=6), and most were related to the ankle or knee joints or thigh muscles and resulted in a  
26 median time refraining from Football Fitness of 2 weeks (interquartile range (IQR) 1.0–3.0). One  
27 participant did not resume Football Fitness after a fall during an indoor warm-up that resulted in a  
28 meniscus lesion. All injuries were managed conservatively. After 12 months, 3 injuries were  
29 reported in 2 participants in CON (see Table 1 ESM).

### 1 3.4 Activity profile during Football Fitness

2 GPS measurements showed that during a session an average of 3.4 (0.5) small-sided matches of 7  
3 min each were played, during which the participants covered 1459 m (447) and performed 80.8  
4 accelerations  $>1 \text{ m/s}^2$  in addition to a total of 157.3 (28.6) activity bouts. Of the activity bouts, 87.5  
5 (23.0) bouts covered 0–5 m, 52.2 (21.2) covered 5–10 m and 17.6 (12.4) covered 10–40 m (see Fig.  
6 2). Mean heart rate (HR) of the sessions was 82.5% (7.3) of maximal HR. Intensity assessed by  
7 time in HR zones has been reported elsewhere <sup>19</sup>.

### 8 3.5 Study outcomes

9 At the 6-month follow-up, the intention-to-treat analyses showed no differences between groups in  
10 any outcomes (see Table 2). At the 12-month follow-up, the analyses showed a significant  
11 difference in mean changes between groups in L1-L4 BMD of  $0.029 \text{ g/cm}^2$  (95% CI: 0.001 to  
12 0.057,  $p=0.040$ ) favouring FFG, whereas a difference in mean changes between groups in  
13 trochanter major BMD of  $0.032 \text{ g/cm}^2$  (-0.004 to 0.069,  $p=0.082$ ) favouring FFG did not reach  
14 statistical significance. At baseline, P1NP was 61.9 (43.3) and 45.7 (28.2)  $\mu\text{g/L}$ , CTX was 353.9  
15 (274.5) and 280.0 (228.1)  $\text{ng/L}$ , and osteocalcin was 20.8 (14.5) and 16.9 (8.5)  $\mu\text{g/L}$  in FFG and  
16 CON, respectively. There were no differences between groups at baseline in BTMs (See Fig. 3). No  
17 differences in mean changes between groups were observed in BTMs at either 6 months ( $p=0.706$ ,  
18 0.844, and 0.754 for CTX, osteocalcin, and P1NP, respectively) or 12 months ( $p=0.671$ , 0.846, and  
19 0.692 for CTX, osteocalcin, and P1NP, respectively). Regarding physical performance outcomes,  
20 we observed significant differences in mean changes between groups of 7.2 kg (0.1 to 14.3,  
21  $p=0.046$ ) in 1RM leg press and  $-4.3 \text{ n NoS}$  (-8.0 to  $-0.7$ ,  $p=0.021$ ) in postural balance, both  
22 favouring FFG.

23 The per-protocol analyses showed significant differences between mean changes of groups in L1-  
24 L4 and trochanter major BMD of  $0.041 \text{ g/cm}^2$  (0.010 to 0.073,  $p=0.012$ ) and  $0.036 \text{ g/cm}^2$  (0.004 to  
25 0.068,  $p=0.030$ ), respectively, favouring FFG (see Table 2 in the ESM and Fig. 4). In total body and  
26 total hip BMD, differences between mean changes of groups of  $0.015 \text{ g/cm}^2$  (-0.001 to 0.031,  
27  $p=0.061$ ) and  $0.039 \text{ g/cm}^2$  (-0.006 to 0.084,  $p=0.085$ ), respectively, favoured FFG, but did not reach  
28 statistical significance (see Table 2 in the ESM). Similarly, differences between mean changes of  
29 groups in 1RM leg press of 7.9 kg (-0.3 to 16.0,  $p=0.059$ ) favouring FFG approached significance  
30 (see Table 2 ESM).

1 No significant differences were observed when comparing those who participated >50% of sessions  
2 with those who participated in <50% of sessions, yet absolute mean relative change values for  
3 BMD, maximal muscle strength, and postural balance outcomes were superior in those who  
4 participated in >50% of sessions (see Table 3 ESM).

5 To assess responsiveness of the Football Fitness, participants were grouped in responders and non-  
6 responders according to their individual differences from baseline to 12 months. At all regions,  
7 more than 70% had increased BMD values and ~90% had improved postural balance (See Table 4  
8 ESM).

9 In the secondary analysis excluding participants receiving bisphosphonates there was a significant  
10 difference in mean changes after 12 months in trochanter major BMD of 0.042 g/cm<sup>2</sup> (0.004 to  
11 0.08, p=0.03) while a difference in mean changes in L1-L4 BMD between groups of 0.030 g/cm<sup>2</sup> (-  
12 0.002 to 0.06) favoured the FFG but did not reach significance (p=0.07; data not shown). The  
13 corresponding per-protocol analysis showed a significant effect in both trochanter major (p=0.02)  
14 and L1-L4 (p=0.03) BMD favouring FFG. As with the analyses of the full study population, no  
15 differences in changes between groups in BTMs were observed at any time point in the secondary  
16 analyses, neither in the per protocol nor with bisphosphonate-treated participants excluded (data not  
17 shown).

#### 18 4 Discussion

19 In this trial we found that 12 months of Football Fitness carried out approximately one hour per  
20 week improved lumbar spine BMD, leg muscle strength and postural balance, but not body  
21 composition, in women treated for breast cancer, compared to usual care. No differences between  
22 the two groups in any outcomes were observed at 6 months. Importantly, Football Fitness was  
23 feasible for this group of participants, yet mean attendance was only half of the offered sessions. In  
24 addition to the intention-to-treat improvement in lumbar spine BMD, the per-protocol analyses  
25 including women participating in at least 1 session per week for 12 months showed significant  
26 improvements in trochanter major BMD compared to CON. The positive effect on BMD is in  
27 accordance with our hypothesis that football has prominent osteogenic potential, even with modest  
28 exercise volumes, over a prolonged period. Contrary to our hypothesis, we found no benefits of  
29 Football Fitness on total body lean or fat mass. As for changes in BMD, this may be due to the low  
30 overall attendance to the intervention of 0.8 sessions per week over the 12-month period.

1 The benefits of Football Fitness on BMD, muscle strength and postural balance are important  
2 findings given the detrimental effects of breast cancer treatment, including chemotherapy and  
3 aromatase inhibitors, which 88% and 28%, respectively, of the participants had been or were being  
4 treated with in the present trial. We have previously shown the efficacy of recreational football on  
5 hip mineralisation in men with prostate cancer undergoing androgen deprivation therapy <sup>14</sup>, and that  
6 finding was confirmed in a subsequent pragmatic multi-centre trial including men with both  
7 localized and advanced prostate cancer <sup>23</sup>. However, in the current trial the ITT analyses showed an  
8 osteogenic effect on lumbar spine BMD, not on hip BMD. The biomechanical loading pattern  
9 during football has been suggested as an explanation for the effect on hip BMD, which may also  
10 count for the spine as a load-bearing part of the axial skeleton <sup>26</sup>. The results of our per-protocol  
11 analyses, where both lumbar spine and trochanter major BMD were improved in FFG compared to  
12 CON after 12 months, are consistent with this theory, and considering the individual responsiveness  
13 with caution, it seemed that, especially the improved BMD values, were associated to higher  
14 adherence to the Football Fitness offer. Moreover, between-group differences favouring FFG in  
15 total body and total hip BMD of 0.015 g/cm<sup>2</sup> and 0.039 g/cm<sup>2</sup>, respectively, approached  
16 significance (p=0.061 and p=0.085), supporting the potential benefits for bone mineralization of  
17 participation in football for women treated for breast cancer. It is likely that the Football Fitness  
18 with frequent high intensity bouts with accelerations and decelerations over short distances and in  
19 varied directions induced osteogenic bone strain of the lumbar spine resulting in a positive net  
20 balance in bone remodelling. Unfortunately, this was not supported by our findings in BTMs. No  
21 differences between groups in BTMs were observed at any time point in the ITT, per protocol, or  
22 without participants receiving bisphosphonates. This may be due to lack of sample power, timing of  
23 the test days, lack of training progression in musculoskeletal stimuli, but also the ability of BTMs to  
24 detect impact of treatment or behaviour on bone turnover over short periods of time, e.g. 4-12  
25 weeks, whereas the 6-month intervals may not reflect the change in osteogenic stimuli induced by  
26 the Football Fitness, but may instead reflect the subsequent normalisation of the BTMs <sup>27</sup>.

27 The concurrent effects on muscle strength and postural balance are of further importance, as  
28 improved muscle strength and postural balance may reduce the occurrence of future falls.  
29 Combined with improved BMD, this may ultimately reduce the risk of fractures in this population  
30 of women treated for breast cancer. Indeed, based on epidemiological studies on the association  
31 between changes in BMD and fracture risk <sup>28</sup>, changes in Z-scores in FFG of 0.301 for L1-L4 and  
32 0.09 for femoral neck in the current trial (data not shown) correspond to estimated reductions of

1 fracture risk of 30 % and 9 % for lumbar spine and femoral neck, respectively. The positive effects  
2 on BMD seen in the present trial are particularly noteworthy given the lack of improvements  
3 described in the majority of previous exercise trials that included both pre- and postmenopausal  
4 breast cancer survivors undertaking exercise programmes lasting at least 1 year <sup>11</sup>. One trial  
5 successfully prevented femoral neck bone loss in premenopausal breast cancer survivors who  
6 performed a median number of 3.3 exercise sessions per week combining step aerobics, jumps and  
7 leaps, and circuit-training either supervised or home-based <sup>29</sup>. In comparison, the participants in the  
8 present trial achieved significant improvements in L1-L4 BMD with a mean of only 0.8 (0.4)  
9 weekly sessions, which underscores the potential of football as an osteogenic exercise modality.  
10 Furthermore, when inspecting individual data, ~70% in FFG had positive BMD values across all  
11 assessed regions (see Table 4 ESM).

12 Some important limitations of the present trial should be emphasised. Most of the participants had  
13 completed at least 3 years of higher education and their mean age was lower than the average for  
14 women treated for breast cancer. The results may therefore not be generalisable to the overall  
15 population of breast cancer survivors. The aim to include 90 women was not achieved due to a  
16 lower than expected recruitment rate, which resulted in a lower study power. Information on  
17 menstrual status was not provided by all participants, which is another limitation because oestrogen  
18 may have a positive influence on bone mineral turnover over 1 year. However, the number of  
19 participants providing this information was ~ 70% in both FFG and CON and the distribution across  
20 the categories “regular monthly cycle”, “irregular cycle” and “no menstruation for  $\geq 1$  year” was  
21 not significantly different between the two groups. Finally, the number of injuries reported by  
22 participants in FFG was higher than in CON. While this raises concern about the safety of Football  
23 Fitness it should also be noted that injuries in FFG were recorded on an ongoing basis and by a  
24 questionnaire at 12 months, while participants in CON only were asked to report musculoskeletal  
25 injuries at 12-months follow-up and the data on injuries in CON may therefore be more prone to  
26 recall bias.

## 27 5 Conclusion

28 We conclude that 1 year of Football Fitness training improves L1-L4 BMD, leg muscle strength and  
29 postural balance in women treated for stage I-III breast cancer. Per-protocol analyses suggest that  
30 participation in at least one weekly session has additional benefits for hip BMD.

## 1 6 Perspectives

2 While regular exercise may counteract some late effects of breast cancer treatment, only few studies  
3 have successfully shown improved BMD with exercise interventions in women treated for breast  
4 cancer <sup>11</sup>. In the present study we show that Football Fitness may be a feasible intervention to  
5 improve both postural balance, muscle strength, and BMD which ultimately may prevent falls,  
6 osteoporosis, and bone fractures. This knowledge adds to the existing evidence on football as a  
7 mean to reduce risk factors for bone fracture in untrained healthy women <sup>18</sup> and elderly men with  
8 prostate cancer, <sup>23,30</sup> and it provides further evidence to the “Football is Medicine” framework  
9 recently suggested by Krstrup et al.<sup>13</sup>

10

### 11 Conflicts of interest:

12 Jacob Uth, Bjørn Frstrup, Victor Sørensen, Eva Wulff Helge, Maja Kjærgaard Christensen, Julie  
13 Boye Kjærgaard, Trine Kjeldgaard Møller, Jørn Wulff Helge, Niklas Rye Jørgensen, Mikael Rørth,  
14 Eva Soelberg Vadstrup, and Peter Krstrup declare that they have no conflict of interest.

### 15 Authors' contributions

16 JU and PK developed the study concept and initiated the project together with MR and ESV. EWH,  
17 JWH, BF, and NRJ further developed the protocol. JU and PK applied for funding. BF and JU set  
18 up the trial database. BF, MKC, JKT, TKM, and JU collected the study data and carried out the  
19 intervention. VS performed the statistical analysis and prepared the tables and figures. JU, VS, and  
20 PK drafted the paper. All authors contributed to and approved the final paper.

### 21 ORCID:

22 Jacob Uth, <http://orcid.org/0000-0003-0619-7134>

23 Bjørn Frstrup, <https://orcid.org/0000-0002-8146-5170>

24 Victor Sørensen, <https://orcid.org/0000-0002-0253-7544>

25 Eva Wulff Helge, <http://orcid.org/0000-0002-4351-0137>

26 Maja Kjærgaard Christensen, Julie Kjærgaard Thomsen, Trine Kjeldgaard Møller,  
27 <https://orcid.org/0000-0002-8337-9575>

28 Jørn Wulff Helge, <http://orcid.org/0000-0001-9724-5423>



1 Niklas Rye Jørgensen, <https://orcid.org/0000-0001-9624-5210>

2 Eva Soelberg Vadstrup, Mikael Rørth,

3 Peter Krstrup <http://orcid.org/0000-0002-1461-9838>

4

5 Figure Captions:

6 **Fig. 1** CONSORT flowchart

7 **Fig. 2** Activity profile during Football Fitness training matches

8 **Fig. 3** Boxplot of P1NP, CTX, and Osteocalcin values at baseline, 6- and 12 months showing  
9 median, interquartile ranges (IQR; 0.25 and 0.75), minimal and maximal values as whiskers, and  
10 outliers as dots ( $>1.5 \times$  IQR). No differences of mean changes between groups were observed.  
11 Mean changes relative to baseline measurements of CTX were 28.7% and -5.3% for FFG and  
12 14.7% and -21.9% for CON at 6 and 12 months, respectively. Mean changes relative to baseline  
13 measurements of P1NP were 11.3% and -14.1% for FFG and 29.0% and -9.8% for CON at 6 and 12  
14 months, respectively. Mean changes relative to baseline measurements of osteocalcin were 2.5%  
15 and -17.2% for FFG and 9.2% and -7.1% for CON at 6 and 12 months, respectively.

16 **Fig. 4** Per-protocol analysis of changes in BMD from baseline to 12 months in FFG (n = 17) and  
17 CON (n = 16)

18 Data availability

19 All data are available upon request.

20

- 21 1. Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, Køtlum JE, Olafsdóttir  
22 E, Pukkala E, Storm HH. NORDCAN--a Nordic tool for cancer information, planning, quality  
23 control and research. *Acta Oncol* 2010;49:725–736.
- 24 2. Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K,  
25 Rimer BK. Changes in weight, body composition, and factors influencing energy balance  
26 among premenopausal breast cancer patients receiving adjuvant chemotherapy. *J Clin Oncol*  
27 2001;19:2381–2389.

- 1 3. Freedman RJ, Aziz N, Albanes D, Hartman T, Danforth D, Hill S, Sebring N, Reynolds JC,  
2 Yanovski JA. Weight and body composition changes during and after adjuvant chemotherapy  
3 in women with breast cancer. *J Clin Endocrinol Metab* 2004;89:2248–2253.
- 4 4. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated  
5 with rapid bone loss in women with early-stage breast cancer. *J Clin Oncol* 2001;19:3306–  
6 3311.
- 7 5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus  
8 tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*  
9 2015;386:1341–1352.
- 10 6. Limburg CE. Screening, prevention, detection, and treatment of cancer therapy-induced bone  
11 loss in patients with breast cancer. *Oncol Nurs Forum* 2007;34:55–63.
- 12 7. Robinson LJ, Yaroslavskiy BB, Griswold RD, Zadorozny EV, Guo L, Tourkova IL, Blair HC.  
13 Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through  
14 estrogen and RANKL-regulated interaction of estrogen receptor-alpha with BCAR1 and Traf6.  
15 *Exp Cell Res* 2009;315:1287–1301.
- 16 8. Kondoh S, Inoue K, Igarashi K, Sugizaki H, Shirode-Fukuda Y, Inoue E, Yu T, Takeuchi JK,  
17 Kanno J, Bonewald LF, Imai Y. Estrogen receptor  $\alpha$  in osteocytes regulates trabecular bone  
18 formation in female mice. *Bone* 2014;60:68–77.
- 19 9. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM,  
20 Creed G. Exercise for preventing and treating osteoporosis in postmenopausal women.  
21 *Cochrane Database Syst Rev* 2011;CD000333.
- 22 10. Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de  
23 Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N,  
24 Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE. Management of Aromatase  
25 Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive  
26 breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and  
27 SIOG. *J Bone Oncol* 2017;7:1–12.

- 1 11. Fornusek CP, Kilbreath SL. Exercise for improving bone health in women treated for stages I-  
2 III breast cancer: a systematic review and meta-analyses. *J Cancer Surviv* 2017;11:525–541.
- 3 12. Beck BR, Daly RM, Singh MAF, Taaffe DR. Exercise and Sports Science Australia (ESSA)  
4 position statement on exercise prescription for the prevention and management of  
5 osteoporosis. *J Sci Med Sport* 2017;20:438–445.
- 6 13. Krstrup P, Williams CA, Mohr M, Hansen PR, Helge EW, Elbe AM, de Sousa M, Dvorak J,  
7 Junge A, Hammami A, Holtermann A, Larsen MN, Kirkendall D, Schmidt JF, Andersen TR,  
8 Buono P, Rørth M, Parnell D, Ottesen L, Bennike S, Nielsen JJ, Mendham AE, Zar A, Uth J,  
9 Hornstrup T, Brasso K, Nybo L, Krstrup BR, Meyer T, Aagaard P, Andersen JL, Hubball H,  
10 Reddy PA, Ryom K, Lobelo F, Barene S, Helge JW, Fatouros IG, Nassis GP, Xu JC, Pettersen  
11 SA, Calbet JA, Seabra A, Rebelo AN, Figueiredo P, Póvoas S, Castagna C, Milanovic Z,  
12 Bangsbo J, Randers MB, Brito J. The ‘Football is Medicine’ platform-scientific evidence,  
13 large-scale implementation of evidence-based concepts and future perspectives. *Scand J Med  
14 Sci Sports* 2018;28 Suppl 1:3–7.
- 15 14. Uth J, Hornstrup T, Christensen JF, Christensen KB, Jørgensen NR, Helge EW, Schmidt JF,  
16 Brasso K, Helge JW, Jakobsen MD, Andersen LL, Rørth M, Midtgaard J, Krstrup P. Football  
17 training in men with prostate cancer undergoing androgen deprivation therapy: activity profile  
18 and short-term skeletal and postural balance adaptations. *Eur J Appl Physiol* 2016;116:471–  
19 480.
- 20 15. Dolan E, Varley I, Ackerman KE, Pereira RMR, Elliott-Sale KJ, Sale C. The Bone Metabolic  
21 Response to Exercise and Nutrition. *Exerc Sport Sci Rev* 2020;48:49–58.
- 22 16. Mohr M, Helge EW, Petersen LF, Lindenskov A, Weihe P, Mortensen J, Jørgensen NR,  
23 Krstrup P. Effects of soccer vs swim training on bone formation in sedentary middle-aged  
24 women. *Eur J Appl Physiol* 2015;115:2671–2679.
- 25 17. Skoradal MB, Helge EW, Jørgensen NR, Mortensen J, Weihe P, Krstrup P, Mohr M.  
26 Osteogenic impact of football training in 55- to 70-year-old women and men with prediabetes.  
27 *Scandinavian Journal of Medicine & Science in Sports* 2018;28:52–60.

- 1 18. Helge EW, Aagaard P, Jakobsen MD, Sundstrup E, Randers MB, Karlsson MK, Krstrup P.  
2 Recreational football training decreases risk factors for bone fractures in untrained  
3 premenopausal women. *Scand J Med Sci Sports* 2010;20 Suppl 1:31–39.
- 4 19. Krstrup P, Hansen PR, Andersen LJ, Jakobsen MD, Sundstrup E, Randers MB, Christiansen  
5 L, Helge EW, Pedersen MT, Søgaard P, Junge A, Dvorak J, Aagaard P, Bangsbo J. Long-term  
6 musculoskeletal and cardiac health effects of recreational football and running for  
7 premenopausal women. *Scandinavian Journal of Medicine & Science in Sports* 2010;20:58–  
8 71.
- 9 20. Uth J, Schmidt JF, Christensen JF, Hornstrup T, Andersen LJ, Hansen PR, Christensen KB,  
10 Andersen LL, Helge EW, Brasso K, Rørth M, Krstrup P, Midtgaard J. Effects of recreational  
11 soccer in men with prostate cancer undergoing androgen deprivation therapy: study protocol  
12 for the ‘FC Prostate’ randomized controlled trial. *BMC Cancer* 2013;13:595.
- 13 21. Uth J, Hornstrup T, Schmidt JF, Christensen JF, Frandsen C, Christensen KB, Helge EW,  
14 Brasso K, Rørth M, Midtgaard J, Krstrup P. Football training improves lean body mass in  
15 men with prostate cancer undergoing androgen deprivation therapy. *Scand J Med Sci Sports*  
16 2014;24 Suppl 1:105–112.
- 17 22. Uth J, Frstrup B, Haahr RD, Brasso K, Helge JW, Rørth M, Midtgaard J, Helge EW, Krstrup  
18 P. Football training over 5 years is associated with preserved femoral bone mineral density in  
19 men with prostate cancer. *Scand J Med Sci Sports* 2018;28 Suppl 1:61–73.
- 20 23. Bjerre ED, Petersen TH, Jørgensen AB, Johansen C, Krstrup P, Langdahl B, Poulsen MH,  
21 Madsen SS, Østergren PB, Borre M, Rørth M, Brasso K, Midtgaard J. Community-based  
22 football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised  
23 controlled trial. *PLoS Med* 2019;16:e1002936.
- 24 24. Uth J, Frstrup B, Sørensen V, Helge EW, Christensen MK, Kjærgaard JB, Møller TK, Mohr  
25 M, Helge JW, Jørgensen NR, Rørth M, Vadstrup ES, Krstrup P. Exercise intensity and  
26 cardiovascular health outcomes after 12 months of football fitness training in women treated  
27 for stage I-III breast cancer: Results from the football fitness After Breast Cancer (ABC)  
28 randomized controlled trial. *Progress in Cardiovascular Diseases* 2020;

- 1 25. Adam, C., Klissouras, V., Ravazzolo, M., Renson, R., Tuxworth, W., Kemper, HCG, van  
2 Mechelen, W, Hlobil, H., Beunen, G., Levarlet-Joye, H., Public and occupational health.  
3 EUROFIT - European test of physical fitness. Council of Europe; 1987.
- 4 26. Lees A, Nolan L. The biomechanics of soccer: a review. *J Sports Sci* 1998;16:211–234.
- 5 27. Banfi G, Lombardi G, Colombini A, Lippi G. Bone metabolism markers in sports medicine.  
6 *Sports Med* 2010;40:697–714.
- 7 28. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S,  
8 Kroger H, Mellstrom D, Meunier PJ, Melton LJ, O’Neill T, Pols H, Reeve J, Silman A,  
9 Tenenhouse A. Predictive value of BMD for hip and other fractures. *J Bone Miner Res*  
10 2005;20:1185–1194.
- 11 29. Saarto T, Sievänen H, Kellokumpu-Lehtinen P, Nikander R, Vehmanen L, Huovinen R,  
12 Kautiainen H, Järvenpää S, Penttinen HM, Utriainen M, Jääskeläinen AS, Elme A, Ruohola J,  
13 Palva T, Vertio H, Rautalahti M, Fogelholm M, Luoto R, Blomqvist C. Effect of supervised  
14 and home exercise training on bone mineral density among breast cancer patients. A 12-month  
15 randomised controlled trial. *Osteoporos Int* 2012;23:1601–1612.
- 16 30. Uth J, Hornstrup T, Christensen JF, Christensen KB, Jørgensen NR, Schmidt JF, Brasso K,  
17 Jakobsen MD, Sundstrup E, Andersen LL, Rørth M, Midtgaard J, Krstrup P, Helge EW.  
18 Efficacy of recreational football on bone health, body composition, and physical functioning in  
19 men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the  
20 FC prostate randomised controlled trial. *Osteoporos Int* 2016;27:1507–1518.

21

**Table 1.** Demographics, medical characteristics, and baseline values of outcomes.

|   | Football Fitness group (n=46) |        |          | Control group (n=22) |        |         |
|---|-------------------------------|--------|----------|----------------------|--------|---------|
|   | N                             | n/mean | SD/%     | N                    | n/mean | SD/%    |
| <b>Demographic characteristics</b>        |                               |        |          |                      |        |         |
| Age (years)                               | 46                            | 47.4   | (9.4)    | 22                   | 50.0   | (9.3)   |
| Married, cohabiting, or in a relationship | 46                            | 30     | (65.2%)  | 22                   | 17     | (77.3%) |
| <b>Ethnicity</b>                          | 46                            |        |          | 22                   |        |         |
| Danish                                    |                               | 42     | (91.3%)  |                      | 20     | (90.9%) |
| Other                                     |                               | 4      | (4.7%)   |                      | 2      | (9.1%)  |
| <b>Educational and working status</b>     | 46                            |        |          | 21                   |        |         |
| > 3 years of higher education             |                               | 39     | (84.8%)  |                      | 14     | (63.6%) |
| Working                                   | 46                            | 34     | (73.9%)  | 22                   | 15     | (68.2%) |
| Sick leave                                | 46                            | 5      | (10.9%)  | 22                   | 4      | (18.2%) |
| <b>Use of addictive substances</b>        |                               |        |          |                      |        |         |
| Smoking                                   | 46                            | 4      | (8.7%)   | 22                   | 1      | (4.5%)  |
| Alcohol intake ( $\geq$ 8 units/week)     | 45                            | 6      | (13.3%)  | 21                   | 3      | (13.6%) |
| <b>Menstrual status</b>                   | 32                            |        |          | 15                   |        |         |
| Regular monthly cycle                     |                               | 0      | (0.0%)   |                      | 0      | (0.0%)  |
| Unregular cycle                           |                               | 5      | (10.9%)  |                      | 5      | (22.7%) |
| No menstruation $\geq$ 1 year             |                               | 27     | (58.7%)  |                      | 10     | (45.5%) |
| <b>Medical characteristics</b>            |                               |        |          |                      |        |         |
| Diagnosed stage of cancer                 | 46                            |        |          | 22                   |        |         |
| I   |                               | 18     | (39.1%)  |                      | 10     | (45.5%) |
| II  |                               | 18     | (39.1%)  |                      | 12     | (54.5%) |
| III                                       |                               | 10     | (21.7%)* |                      | 0      | (0.0%)  |
| <b>Surgery</b>                            |                               |        |          |                      |        |         |
| Time since surgery (years)                | 46                            | 3.1    | (1.9)    | 22                   | 3.4    | (3.0)   |
| Mastectomy                                | 46                            | 19     | (41.3%)  | 22                   | 9      | (40.9%) |
| Lumpectomy                                | 46                            | 27     | (58.7%)  | 22                   | 13     | (59.1%) |
| <b>Previous therapy</b>                   |                               |        |          |                      |        |         |
| Radiotherapy                              | 46                            | 38     | (82.6%)  | 22                   | 17     | (77.3%) |
| Chemotherapy                              | 46                            | 43     | (93.5%)  | 21                   | 18     | (81.8%) |
| <b>Current treatment</b>                  |                               |        |          |                      |        |         |
| Tamoxifen                                 | 46                            | 25     | (54.3%)  | 22                   | 11     | (50.0%) |
| Aromatase inhibitors                      | 46                            | 11     | (23.9%)  | 22                   | 7      | (31.8%) |
| Trastuzumab                               | 46                            | 15     | (32.6%)  | 22                   | 6      | (27.3%) |
| <b>Zoledronic acid</b>                    |                               |        |          |                      |        |         |
| Before inclusion (days)                   | 7                             | 180    | (111)    | 2                    | 70     | (10)    |
| After inclusion (days)                    | 7                             | 123    | (99)     | 2                    | 88     | (93)    |
| <b>Baseline measurements</b>              |                               |        |          |                      |        |         |
| <b>Bone densitometry</b>                  |                               |        |          |                      |        |         |
| Total body BMD (g/cm <sup>2</sup> )       | 46                            | 1.190  | (0.103)  | 22                   | 1.200  | (0.101) |
| T-score                                   |                               | 1.010  | (1.030)  |                      | 1.170  | (1.000) |

|   |    |        |         |    |        |         |
|---|----|--------|---------|----|--------|---------|
| Z-score                                   |    | 1.050  | (1.020) |    | 1.080  | (0.851) |
| L1-L4 BMD (g/cm <sup>2</sup> )            | 44 | 1.150  | (0.128) | 21 | 1.200  | (0.153) |
| T-score                                   |    | -0.252 | (1.070) |    | 0.176  | (1.270) |
| Z-score                                   |    | -0.056 | (1.230) |    | 0.287  | (1.160) |
| Total hip BMD (g/cm <sup>2</sup> )        | 45 | 0.973  | (0.111) | 22 | 1.000  | (0.112) |
| Femoral neck BMD (g/cm <sup>2</sup> )     | 46 | 0.941  | (0.109) | 22 | 0.980  | (0.118) |
| T-score                                   |    | -0.342 | (0.906) |    | -0.001 | (0.979) |
| Z-score                                   |    | 0.078  | (0.791) |    | 0.271  | (0.916) |
| Trochanter major BMD (g/cm <sup>2</sup> ) | 46 | 0.782  | (0.106) | 22 | 0.814  | (0.100) |
| Femoral shaft BMD (g/cm <sup>2</sup> )    | 45 | 1.160  | (0.136) | 22 | 1.180  | (0.145) |
| <b>Body composition</b>                   |    |        |         |    |        |         |
| Body mass index (kg/m <sup>2</sup> )      | 46 | 25.5   | (4.9)   | 22 | 26.4   | (4.6)   |
| Lean body mass (kg)                       | 46 | 42.6   | (4.0)   | 22 | 43.5   | (5.2)   |
| Fat percentage (%)                        | 46 | 38.0   | (7.7)   | 22 | 40.4   | (7.0)   |
| <b>Physical function</b>                  |    |        |         |    |        |         |
| 1RM leg press (kg)                        | 45 | 86.2   | (23.5)  | 21 | 85.7   | (25.6)  |
| 1RM leg extension (kg)                    | 46 | 43.1   | (7.7)   | 22 | 44.3   | (9.4)   |
| Postural balance (n NoS)                  | 46 | 15.5   | (9.1)   | 22 | 15.9   | (7.1)   |

Difference between groups are annotated with \* (P < 0.05). Continuous variables were analysed with two-sample t-tests. Categorical variables were analysed with Chi<sup>2</sup>-tests. Measurements of BMD of lower limbs are reported as the mean of the left and right values. Abbreviations: Bone mineral density (BMD), 1 repetition maximum (1RM), need of support (NoS).


**Table 2.** Estimated mean differences within and between groups at 6 and 12 months.


| Measurements              | Football Fitness group |             |                   | Control group |             |                   | Est. Δ between mean changes of groups |                   |              |             |
|---------------------------|------------------------|-------------|-------------------|---------------|-------------|-------------------|---------------------------------------|-------------------|--------------|-------------|
|                           | n                      | Est. mean Δ | 0.95 CI           | n             | Est. mean Δ | 0.95 CI           | Est. mean Δ                           | 0.95 CI           | P value      | %           |
| <b>0-6 months</b>         |                        |             |                   |               |             |                   |                                       |                   |              |             |
| <b>Bone densitometry</b>  |                        |             |                   |               |             |                   |                                       |                   |              |             |
| <b>(g/cm<sup>2</sup>)</b> |                        |             |                   |               |             |                   |                                       |                   |              |             |
| Total body BMD            | 35                     | 0.004       | (-0.004 to 0.012) | 19            | -0.005      | (-0.015 to 0.006) | 0.009                                 | (-0.004 to 0.022) | 0.175        | 0.8%        |
| L1-L4 BMD                 | 33                     | 0.013       | (0.003 to 0.023)  | 18            | 0.001       | (-0.012 to 0.015) | 0.011                                 | (-0.005 to 0.028) | 0.184        | 0.9%        |
| Total hip BMD             | 35                     | 0.002       | (-0.024 to 0.028) | 18            | -0.013      | (-0.049 to 0.023) | 0.015                                 | (-0.030 to 0.059) | 0.512        | 1.5%        |
| Femoral neck BMD          | 35                     | -0.005      | (-0.038 to 0.028) | 18            | -0.012      | (-0.058 to 0.034) | 0.007                                 | (-0.049 to 0.064) | 0.800        | 0.7%        |
| Trochanter m. BMD         | 35                     | 0.010       | (-0.012 to 0.030) | 18            | -0.015      | (-0.044 to 0.014) | 0.025                                 | (-0.011 to 0.061) | 0.170        | 3.2%        |
| Femoral shaft BMD         | 35                     | -0.001      | (-0.036 to 0.034) | 18            | -0.011      | (-0.06 to 0.037)  | 0.011                                 | (-0.049 to 0.071) | 0.724        | 0.9%        |
| <b>Body composition</b>   |                        |             |                   |               |             |                   |                                       |                   |              |             |
| Body mass index           | 35                     | -0.1        | (-0.4 to 0.2)     | 19            | -0.2        | (-0.6 to 0.2)     | 0.1                                   | (-0.4 to 0.6)     | 0.593        | 0.4%        |
| <b>(kg/m<sup>2</sup>)</b> |                        |             |                   |               |             |                   |                                       |                   |              |             |
| Lean body mass (kg)       | 35                     | 0.3         | (-0.3 to 0.8)     | 19            | 0.0         | (-0.8 to 0.7)     | 0.3                                   | (-0.6 to 1.2)     | 0.536        | 0.7%        |
| Fat percentage (%)        | 35                     | -0.7        | (-1.4 to 0.0)     | 19            | -0.5        | (-1.4 to 0.5)     | -0.2                                  | (-1.4 to 1.0)     | 0.700        | -0.5%       |
| <b>Physical function</b>  |                        |             |                   |               |             |                   |                                       |                   |              |             |
| IRM leg press (kg)        | 35                     | 1.0         | (-2.8 to 4.7)     | 19            | -3.1        | (-8.2 to 2.0)     | 4.1                                   | (-2.3 to 10.4)    | 0.206        | 4.8%        |
| IRM leg extension (kg)    | 35                     | 1.7         | (0.1 to 3.3)      | 19            | 2.2         | (0.1 to 4.4)      | -0.5                                  | (-3.2 to 2.2)     | 0.696        | -1.1%       |
| Postural balance (n NoS)  | 35                     | -4.3        | (-6.0 to -2.6)    | 18            | -2.6        | (-5.1 to -0.2)    | -1.7                                  | (-4.7 to 1.4)     | 0.272        | -10.9%      |
| <b>0-12 months</b>        |                        |             |                   |               |             |                   |                                       |                   |              |             |
| <b>Bone densitometry</b>  |                        |             |                   |               |             |                   |                                       |                   |              |             |
| <b>(g/cm<sup>2</sup>)</b> |                        |             |                   |               |             |                   |                                       |                   |              |             |
| Total body BMD            | 33                     | 0.015       | (0.007 to 0.023)  | 16            | 0.008       | (-0.004 to 0.019) | 0.007                                 | (-0.007 to 0.021) | 0.314        | 0.6%        |
| L1-L4 BMD                 | 32                     | 0.027       | (0.011 to 0.043)  | 16            | -0.002      | (-0.025 to 0.021) | 0.029                                 | (0.001 to 0.057)  | <b>0.040</b> | <b>2.5%</b> |
| Total hip BMD             | 33                     | 0.011       | (-0.015 to 0.038) | 16            | -0.009      | (-0.045 to 0.028) | 0.020                                 | (-0.025 to 0.065) | 0.371        | 2.0%        |
| Femoral neck BMD          | 33                     | 0.004       | (-0.028 to 0.037) | 16            | -0.007      | (-0.053 to 0.038) | 0.011                                 | (-0.045 to 0.068) | 0.683        | 1.2%        |
| Trochanter m. BMD         | 33                     | 0.018       | (-0.003 to 0.040) | 16            | -0.014      | (-0.043 to 0.016) | 0.032                                 | (-0.004 to 0.069) | 0.082        | 4.0%        |
| Femoral shaft BMD         | 33                     | 0.010       | (-0.026 to 0.045) | 16            | -0.003      | (-0.052 to 0.047) | 0.012                                 | (-0.049 to 0.073) | 0.695        | 1.0%        |




| <b>Body composition</b>              |    |      |                |    |      |                |      |                |              |               |
|--------------------------------------|----|------|----------------|----|------|----------------|------|----------------|--------------|---------------|
| Body mass index (kg/m <sup>2</sup> ) | 33 | -0.2 | (-0.6 to 0.2)  | 16 | -0.1 | (-0.7 to 0.5)  | -0.1 | (-0.8 to 0.6)  | 0.808        | -0.4%         |
| Lean body mass (kg)                  | 33 | -0.2 | (-0.8 to 0.3)  | 16 | 0.0  | (-0.8 to 0.8)  | -0.2 | (-1.2 to 0.8)  | 0.663        | -0.5%         |
| Fat percentage (%)                   | 33 | -0.3 | (-1.2 to 0.6)  | 16 | 0.0  | (-1.3 to 1.3)  | -0.3 | (-1.8 to 1.3)  | 0.742        | -0.8%         |
| <b>Physical function</b>             |    |      |                |    |      |                |      |                |              |               |
| 1RM leg press (kg)                   | 28 | 2.2  | (-1.9 to 6.4)  | 14 | -5.0 | (-10.8 to 0.8) | 7.2  | (0.1 to 14.3)  | <b>0.046</b> | <b>8.4%</b>   |
| 1RM leg extension (kg)               | 28 | 4.3  | (0.6 to 8.0)   | 14 | 6.4  | (1.2 to 11.6)  | -2.1 | (-8.5 to 4.3)  | 0.509        | -4.8%         |
| Postural balance (n NoS)             | 27 | -5.9 | (-8.0 to -3.9) | 13 | -1.6 | (-4.6 to 1.4)  | -4.3 | (-8.0 to -0.7) | <b>0.021</b> | <b>-27.5%</b> |

Intention-to-treat analyses of outcomes were performed with linear mixed model analyses including all available data. Hence, reported n's are available data at endpoints of time intervals (6 and 12 months, respectively). Measurements of BMD of lower limbs are reported as the mean of the left and right values. Abbreviations: bone mineral density (BMD), one repetition maximum (1RM), need of support (NoS).






sms\_13963\_f2.jpg



sms\_13963\_f3.jpg



sms\_13963\_f4.jpg